Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. Prolong Pharmaceuticals' business strategy is to use its proprietary know-how, processes and relationships to become the world-leader in developing PEGylated products. The Company expects to create revenues from the licensing of its products to multinational pharmaceutical companies, through the direct sale of PEGylated biopharmaceuticals that it independently develops, and by developing R&D relationships with other biotechnology companies developing therapeutic proteins.